Study · Randomized controlled trial · n = 44 · 2015

8 results

Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.

Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA

Obesity research & clinical practice11 Apr 2015Cited by 75 (Europe PMC)

PMID25870084DOI10.1016/j.orcp.2015.03.005PepBankPUB-25870084

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese adults with subclinical binge eating, liraglutide for 12 weeks significantly improved binge eating.
In plain wordsIn obese adults with some binge eating, liraglutide for 12 weeks was linked to less binge eating.
Peptide
Liraglutide
Outcome
DecreaseBinge eating score
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Appetite and food intake · Mental health and mood
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008401
02HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese adults with subclinical binge eating, liraglutide for 12 weeks significantly reduced body weight.
In plain wordsIn obese adults with some binge eating, liraglutide for 12 weeks was linked to lower body weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008402
03HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese adults with subclinical binge eating, liraglutide for 12 weeks significantly reduced BMI.
In plain wordsIn obese adults with some binge eating, liraglutide for 12 weeks was linked to a lower BMI.
Peptide
Liraglutide
Outcome
DecreaseBMI
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008403
04HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese adults with subclinical binge eating, liraglutide for 12 weeks significantly reduced waist circumference.
In plain wordsIn obese adults with some binge eating, liraglutide for 12 weeks was linked to a smaller waist.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008404
05HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese adults with subclinical binge eating, liraglutide for 12 weeks significantly reduced systolic blood pressure.
In plain wordsIn obese adults with some binge eating, liraglutide for 12 weeks was linked to lower systolic blood pressure.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008405
06HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese adults with subclinical binge eating, liraglutide for 12 weeks significantly reduced fasting glucose.
In plain wordsIn obese adults with some binge eating, liraglutide for 12 weeks was linked to lower fasting glucose.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008406
07HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese adults with subclinical binge eating, liraglutide for 12 weeks significantly reduced total cholesterol.
In plain wordsIn obese adults with some binge eating, liraglutide for 12 weeks was linked to lower total cholesterol.
Peptide
Liraglutide
Outcome
DecreaseTotal cholesterol
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008407
08HumanRandomized controlled trialMechanism
In non-diabetic obese adults with subclinical binge eating, ghrelin levels rose significantly during 12 weeks of liraglutide treatment.
In plain wordsIn obese adults with some binge eating, ghrelin levels rose during 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
IncreaseGhrelin level
Study
n = 44
Comparator
Control group (standard diet and exercise advice only)
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Ghrelin levels were significantly increased which may potentially diminish the weight loss effects of liraglutide beyond the intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks.
Summary · context
All participants received standard advice for diet and exercise.
Report a problemFND-2587008408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06243536

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

University Hospital Sestre Milosrdnicen = 60est. 1 Feb 2024 to est. 31 Dec 2024

Type 2 Diabetes · Overweight · Disordered Eating Behaviors

Trial page ClinicalTrials.govUpdated 6 Feb 2024

CompletedPhase 4NCT01739049

Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese

Universiti Kebangsaan Malaysia Medical Centren = 42Nov 2012 to Jan 2015

Binge Eating Behaviour

Trial page ClinicalTrials.govUpdated 4 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.